|
Sen. Kwame Raoul
Filed: 4/23/2012
| | 09700HB5233sam002 | | LRB097 20167 RPM 68732 a |
|
|
1 | | AMENDMENT TO HOUSE BILL 5233
|
2 | | AMENDMENT NO. ______. Amend House Bill 5233 by replacing |
3 | | everything after the enacting clause with the following:
|
4 | | "Section 5. The Illinois Food, Drug and Cosmetic Act is |
5 | | amended by changing Sections 2.4, 3.22, 5, and 6 as follows:
|
6 | | (410 ILCS 620/2.4) (from Ch. 56 1/2, par. 502.4)
|
7 | | Sec. 2.4.
(a) "Drug" means (1) articles recognized in the |
8 | | official United
States Pharmacopoeia - National Formulary, |
9 | | official Homeopathic Pharmacopoeia
of the United
States, |
10 | | United States Dispensatory, or Remington's Practice of |
11 | | Pharmacy,
or any supplement to any of them; and (2)
articles |
12 | | intended for use in the diagnosis, cure, mitigation, treatment |
13 | | or
prevention of disease in man or other animals; and (3) |
14 | | articles (other than
food) intended to affect the structure or |
15 | | any function of the body of man
or other animals; and (4) |
16 | | articles intended for use as a component of any
article |
|
| | 09700HB5233sam002 | - 2 - | LRB097 20167 RPM 68732 a |
|
|
1 | | specified in clause (1), (2) or (3); but does not include |
2 | | devices
or their components, parts or accessories.
|
3 | | (b) "Synthetic drug product" means any product that |
4 | | contains a substance defined as a controlled substance under |
5 | | subsections (d) and (e) of Section 204 of the Illinois |
6 | | Controlled Substances Act. Products approved by the U.S. Food |
7 | | and Drug Administration for human consumption are not synthetic |
8 | | drug products. |
9 | | (Source: P.A. 84-891.)
|
10 | | (410 ILCS 620/3.22) (from Ch. 56 1/2, par. 503.22)
|
11 | | Sec. 3.22.
(a) Whoever knowingly distributes, or possesses |
12 | | with intent to
distribute, human growth hormone for any use in |
13 | | humans other than the
treatment of a disease or other |
14 | | recognized medical condition, where the use
has been authorized |
15 | | by the Secretary of Health and Human Services and under
the |
16 | | order of a physician, is guilty of a Class 3 felony, and may be |
17 | | fined
an amount not to exceed $50,000. As used in this Section, |
18 | | the term "human growth hormone" means somatrem, somatropin, or |
19 | | an analogue of either of them.
|
20 | | (b) Whoever distributes, or possesses with intent to |
21 | | distribute, a synthetic drug product or a drug that is |
22 | | misbranded under this Act is guilty of a Class 2 felony and may |
23 | | be fined an amount not to exceed $100,000. A person convicted |
24 | | of a second or subsequent violation of this Section is guilty |
25 | | of a Class 1 felony, the fine for which shall not exceed |
|
| | 09700HB5233sam002 | - 3 - | LRB097 20167 RPM 68732 a |
|
|
1 | | $250,000. |
2 | | (c) Whoever falsely advertises a synthetic drug product is |
3 | | guilty of a Class 3 felony and may be fined an amount not to |
4 | | exceed $100,000. |
5 | | (d) Whoever commits any offense set forth in this Section |
6 | | and the offense
involves an individual under 18 years of age is |
7 | | punishable by not more than
10 years imprisonment, and twice |
8 | | the fine authorized above. Any conviction
for a violation of |
9 | | this Section shall be considered a violation of the
Illinois |
10 | | Controlled Substances Act for the purposes of forfeiture under
|
11 | | Section 505 of such Act. As used in this Section the term |
12 | | "human growth
hormone" means somatrem, somatropin, or an |
13 | | analogue of either of them. The
Department of State Police and |
14 | | Department of Professional Regulation are
authorized to |
15 | | investigate offenses punishable by this Section.
|
16 | | (e) Any person convicted under this Section is subject to |
17 | | the forfeiture provisions set forth in subsections (c), (d), |
18 | | (e), (f), (g), (h), and (i) of Section 3.23 of this Act. |
19 | | (Source: P.A. 87-754.)
|
20 | | (410 ILCS 620/5) (from Ch. 56 1/2, par. 505)
|
21 | | Sec. 5.
(a) A person who violates any of the provisions of |
22 | | this Act,
other than Sections 3.22 and 6, is guilty of a Class |
23 | | C misdemeanor; but if
the violation is committed after a |
24 | | conviction of such person under this
Section has become final, |
25 | | the person shall be guilty of a Class A
misdemeanor. A person |
|
| | 09700HB5233sam002 | - 4 - | LRB097 20167 RPM 68732 a |
|
|
1 | | who violates the provisions of Section 6 of this Act
is guilty |
2 | | of a Class A misdemeanor; but if the violation is committed |
3 | | after
a conviction of such person under this Section has become |
4 | | final, the person
shall be guilty of a Class 4 felony.
|
5 | | (b) No person is subject to the penalties of subsection (a) |
6 | | of this
Section for (1) violating Section 3.1 or 3.3 if he |
7 | | establishes a guaranty or
undertaking signed by and containing |
8 | | the name and address of the person
residing in the State of |
9 | | Illinois from whom he received the article in good
faith, to |
10 | | the effect that the article is not adulterated or misbranded
|
11 | | within the meaning of this Act, designating this Act; or (2) |
12 | | for having
violated clause (2) of Section 3.16 if such person |
13 | | acted in good faith and
had no reason to believe that the use |
14 | | of the punch, die, plate, stone or
other thing involved would |
15 | | result in a drug being a counterfeit drug, or
for having |
16 | | violated clause (3) of Section 3.16 if the person doing the act
|
17 | | or causing it to be done acted in good faith and had no reason |
18 | | to believe
that the drug was a counterfeit drug.
|
19 | | (c) No publisher, radio-broadcast licensee, agency or |
20 | | medium for the
dissemination of an advertisement, except the |
21 | | manufacturer, packer,
distributor or seller of the article to |
22 | | which a false advertisement relates
is liable under this |
23 | | Section for the dissemination of such false
advertisement |
24 | | unless he has refused on the request of the Director to
furnish |
25 | | the Director the name and post office address of the |
26 | | manufacturer,
packer, distributor, seller or advertising |
|
| | 09700HB5233sam002 | - 5 - | LRB097 20167 RPM 68732 a |
|
|
1 | | agency residing in the State of
Illinois who causes him to |
2 | | disseminate such advertisement.
|
3 | | (d) No person shall be subject to the penalties of |
4 | | subsection (a) of
this Section for a violation of Section 3 |
5 | | involving misbranded food if the
violation exists solely |
6 | | because the food is misbranded under subsection
(c) of Section |
7 | | 11 because of its advertising, and no person shall be
subject |
8 | | to the penalties of subsection (a) of this Section for such a
|
9 | | violation unless the violation is committed with the intent to |
10 | | defraud
or mislead.
|
11 | | (Source: P.A. 86-704; 87-754.)
|
12 | | (410 ILCS 620/6) (from Ch. 56 1/2, par. 506)
|
13 | | Sec. 6.
(a) When an authorized agent of the Director finds |
14 | | or has probable
cause to believe that any food, drug, device or |
15 | | cosmetic is adulterated or
so misbranded as to be dangerous or |
16 | | fraudulent within the meaning of this
Act , or is in violation |
17 | | of Section 12, 17 or 17.1 of this Act, or is suspected to be a |
18 | | synthetic drug product, he or she
shall affix to such article a |
19 | | tag or other appropriate marking
giving notice that the article |
20 | | is or is suspected of being adulterated or
misbranded and has |
21 | | been detained or embargoed and warning all persons not
to |
22 | | remove or dispose of such article by sale or otherwise until |
23 | | permission
for removal or disposal is given by such agent or |
24 | | the court. It is unlawful
for any person to remove or dispose |
25 | | of such detained or embargoed article
by sale or otherwise |
|
| | 09700HB5233sam002 | - 6 - | LRB097 20167 RPM 68732 a |
|
|
1 | | without such permission.
|
2 | | (b) When an article detained or embargoed under subsection |
3 | | (a) of this
Section is found by such agent to be adulterated or |
4 | | misbranded or to be
in violation of Section 12, 17 or 17.1 of |
5 | | this Act or is suspected to be a synthetic drug product ,
he or |
6 | | she shall petition the
circuit court in whose jurisdiction the |
7 | | article is detained or embargoed
for a libel for condemnation |
8 | | of such article. When such agent finds that an
article so |
9 | | detained or embargoed is not adulterated or misbranded or is |
10 | | not a synthetic drug product , he or
she shall remove the tag or |
11 | | other marking.
|
12 | | (c) If the court finds that a detained or embargoed article |
13 | | is
adulterated or misbranded, such article shall, after entry |
14 | | of the judgment, be
destroyed at the expense of the claimant |
15 | | thereof, under the supervision
of such agent, and all court |
16 | | costs and fees, and storage and other proper
expenses, shall be |
17 | | taxed against the claimant of such article or his or her
agent. |
18 | | However, when the adulteration or misbranding can be corrected |
19 | | by proper
labeling or processing of the article, the court, |
20 | | after entry of the judgment
and after such costs, fees and |
21 | | expenses have been paid and a good and
sufficient bond, |
22 | | conditioned that such article shall be so labeled or
processed, |
23 | | has been executed, may by order direct that such article be
|
24 | | delivered to the claimant thereof for such labeling or |
25 | | processing under the
supervision of an agent of the Director. |
26 | | The expense of such supervision
shall be paid by the claimant. |
|
| | 09700HB5233sam002 | - 7 - | LRB097 20167 RPM 68732 a |
|
|
1 | | The article shall be returned to the claimant
and the bond |
2 | | shall be discharged on the representation to the court by the
|
3 | | Director that the article is no longer in violation of this |
4 | | Act, and that
the expenses of such supervision have been paid.
|
5 | | (d) Whenever the Director or any of his or her authorized |
6 | | agents finds
in any room, building, vehicle of transportation |
7 | | or other structure, any
meat, sea food, poultry, vegetable, |
8 | | fruit or other perishable articles
which contain any filthy, |
9 | | decomposed or putrid substance, or that may be
poisonous or |
10 | | deleterious to health or otherwise unsafe, the same being
|
11 | | hereby declared to be a nuisance, the Director or his or her |
12 | | authorized
agent shall condemn or destroy the same, or in any |
13 | | other manner render the
same unusable as human food.
|
14 | | (Source: P.A. 85-564.)
|
15 | | Section 10. The Illinois Controlled Substances Act is |
16 | | amended by changing Section 204 as follows: |
17 | | (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204) |
18 | | Sec. 204. (a) The controlled substances listed in this |
19 | | Section are
included in Schedule I. |
20 | | (b) Unless specifically excepted or unless listed in |
21 | | another
schedule, any of the following opiates, including their |
22 | | isomers,
esters, ethers, salts, and salts of isomers, esters, |
23 | | and ethers,
whenever the existence of such isomers, esters, |
24 | | ethers and salts is
possible within the specific chemical |
|
| | 09700HB5233sam002 | - 8 - | LRB097 20167 RPM 68732 a |
|
|
1 | | designation: |
2 | | (1) Acetylmethadol; |
3 | | (1.1) Acetyl-alpha-methylfentanyl |
4 | | (N-[1-(1-methyl-2-phenethyl)-
|
5 | | 4-piperidinyl]-N-phenylacetamide); |
6 | | (2) Allylprodine; |
7 | | (3) Alphacetylmethadol, except
|
8 | | levo-alphacetylmethadol (also known as levo-alpha-
|
9 | | acetylmethadol, levomethadyl acetate, or LAAM); |
10 | | (4) Alphameprodine; |
11 | | (5) Alphamethadol; |
12 | | (6) Alpha-methylfentanyl
|
13 | | (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
|
14 | | propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
|
15 | | propanilido) piperidine; |
16 | | (6.1) Alpha-methylthiofentanyl
|
17 | | (N-[1-methyl-2-(2-thienyl)ethyl-
|
18 | | 4-piperidinyl]-N-phenylpropanamide); |
19 | | (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP); |
20 | | (7.1) PEPAP
|
21 | | (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine); |
22 | | (8) Benzethidine; |
23 | | (9) Betacetylmethadol; |
24 | | (9.1) Beta-hydroxyfentanyl
|
25 | | (N-[1-(2-hydroxy-2-phenethyl)-
|
26 | | 4-piperidinyl]-N-phenylpropanamide); |
|
| | 09700HB5233sam002 | - 9 - | LRB097 20167 RPM 68732 a |
|
|
1 | | (10) Betameprodine; |
2 | | (11) Betamethadol; |
3 | | (12) Betaprodine; |
4 | | (13) Clonitazene; |
5 | | (14) Dextromoramide; |
6 | | (15) Diampromide; |
7 | | (16) Diethylthiambutene; |
8 | | (17) Difenoxin; |
9 | | (18) Dimenoxadol; |
10 | | (19) Dimepheptanol; |
11 | | (20) Dimethylthiambutene; |
12 | | (21) Dioxaphetylbutyrate; |
13 | | (22) Dipipanone; |
14 | | (23) Ethylmethylthiambutene; |
15 | | (24) Etonitazene; |
16 | | (25) Etoxeridine; |
17 | | (26) Furethidine; |
18 | | (27) Hydroxpethidine; |
19 | | (28) Ketobemidone; |
20 | | (29) Levomoramide; |
21 | | (30) Levophenacylmorphan; |
22 | | (31) 3-Methylfentanyl
|
23 | | (N-[3-methyl-1-(2-phenylethyl)-
|
24 | | 4-piperidyl]-N-phenylpropanamide); |
25 | | (31.1) 3-Methylthiofentanyl
|
26 | | (N-[(3-methyl-1-(2-thienyl)ethyl-
|
|
| | 09700HB5233sam002 | - 10 - | LRB097 20167 RPM 68732 a |
|
|
1 | | 4-piperidinyl]-N-phenylpropanamide); |
2 | | (32) Morpheridine; |
3 | | (33) Noracymethadol; |
4 | | (34) Norlevorphanol; |
5 | | (35) Normethadone; |
6 | | (36) Norpipanone; |
7 | | (36.1) Para-fluorofentanyl
|
8 | | (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
|
9 | | 4-piperidinyl]propanamide); |
10 | | (37) Phenadoxone; |
11 | | (38) Phenampromide; |
12 | | (39) Phenomorphan; |
13 | | (40) Phenoperidine; |
14 | | (41) Piritramide; |
15 | | (42) Proheptazine; |
16 | | (43) Properidine; |
17 | | (44) Propiram; |
18 | | (45) Racemoramide; |
19 | | (45.1) Thiofentanyl
|
20 | | (N-phenyl-N-[1-(2-thienyl)ethyl-
|
21 | | 4-piperidinyl]-propanamide); |
22 | | (46) Tilidine; |
23 | | (47) Trimeperidine; |
24 | | (48) Beta-hydroxy-3-methylfentanyl (other name:
|
25 | | N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
|
26 | | N-phenylpropanamide). |
|
| | 09700HB5233sam002 | - 11 - | LRB097 20167 RPM 68732 a |
|
|
1 | | (c) Unless specifically excepted or unless listed in |
2 | | another
schedule, any of the following opium derivatives, its |
3 | | salts, isomers
and salts of isomers, whenever the existence of |
4 | | such salts, isomers and
salts of isomers is possible within the |
5 | | specific chemical designation: |
6 | | (1) Acetorphine; |
7 | | (2) Acetyldihydrocodeine; |
8 | | (3) Benzylmorphine; |
9 | | (4) Codeine methylbromide; |
10 | | (5) Codeine-N-Oxide; |
11 | | (6) Cyprenorphine; |
12 | | (7) Desomorphine; |
13 | | (8) Diacetyldihydromorphine (Dihydroheroin); |
14 | | (9) Dihydromorphine; |
15 | | (10) Drotebanol; |
16 | | (11) Etorphine (except hydrochloride salt); |
17 | | (12) Heroin; |
18 | | (13) Hydromorphinol; |
19 | | (14) Methyldesorphine; |
20 | | (15) Methyldihydromorphine; |
21 | | (16) Morphine methylbromide; |
22 | | (17) Morphine methylsulfonate; |
23 | | (18) Morphine-N-Oxide; |
24 | | (19) Myrophine; |
25 | | (20) Nicocodeine; |
26 | | (21) Nicomorphine; |
|
| | 09700HB5233sam002 | - 12 - | LRB097 20167 RPM 68732 a |
|
|
1 | | (22) Normorphine; |
2 | | (23) Pholcodine; |
3 | | (24) Thebacon. |
4 | | (d) Unless specifically excepted or unless listed in |
5 | | another
schedule, any material, compound, mixture, or |
6 | | preparation which contains
any quantity of the following |
7 | | hallucinogenic substances, or which
contains any of its salts, |
8 | | isomers and salts of isomers, whenever the
existence of such |
9 | | salts, isomers, and salts of isomers is possible
within the |
10 | | specific chemical designation (for the purposes of this
|
11 | | paragraph only, the term "isomer" includes the optical, |
12 | | position and
geometric isomers): |
13 | | (1) 3,4-methylenedioxyamphetamine
|
14 | | (alpha-methyl,3,4-methylenedioxyphenethylamine,
|
15 | | methylenedioxyamphetamine, MDA); |
16 | | (1.1) Alpha-ethyltryptamine
|
17 | | (some trade or other names: etryptamine;
|
18 | | MONASE; alpha-ethyl-1H-indole-3-ethanamine;
|
19 | | 3-(2-aminobutyl)indole; a-ET; and AET); |
20 | | (2) 3,4-methylenedioxymethamphetamine (MDMA); |
21 | | (2.1) 3,4-methylenedioxy-N-ethylamphetamine
|
22 | | (also known as: N-ethyl-alpha-methyl-
|
23 | | 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
|
24 | | and MDEA); |
25 | | (2.2) N-Benzylpiperazine (BZP); |
26 | | (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA); |
|
| | 09700HB5233sam002 | - 13 - | LRB097 20167 RPM 68732 a |
|
|
1 | | (4) 3,4,5-trimethoxyamphetamine (TMA); |
2 | | (5) (Blank); |
3 | | (6) Diethyltryptamine (DET); |
4 | | (7) Dimethyltryptamine (DMT); |
5 | | (7.1) 5-Methoxy-diallyltryptamine; |
6 | | (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP); |
7 | | (9) Ibogaine (some trade and other names:
|
8 | | 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
|
9 | | 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
|
10 | | indole; Tabernanthe iboga); |
11 | | (10) Lysergic acid diethylamide; |
12 | | (10.1) Salvinorin A; |
13 | | (10.5) Salvia divinorum (meaning all parts of the plant |
14 | | presently classified
botanically as Salvia divinorum, |
15 | | whether growing or not, the
seeds thereof, any extract from |
16 | | any part of that plant, and every compound,
manufacture, |
17 | | salts, isomers, and salts of
isomers whenever the existence |
18 | | of such salts, isomers, and salts of
isomers is possible |
19 | | within the specific chemical designation, derivative, |
20 | | mixture, or preparation of that plant, its
seeds or |
21 | | extracts);
|
22 | | (11) 3,4,5-trimethoxyphenethylamine (Mescaline); |
23 | | (12) Peyote (meaning all parts of the plant presently |
24 | | classified
botanically as Lophophora williamsii
Lemaire, |
25 | | whether growing or not, the
seeds thereof, any extract from |
26 | | any part of that plant, and every compound,
manufacture, |
|
| | 09700HB5233sam002 | - 14 - | LRB097 20167 RPM 68732 a |
|
|
1 | | salts, derivative, mixture, or preparation of that plant, |
2 | | its
seeds or extracts); |
3 | | (13) N-ethyl-3-piperidyl benzilate (JB 318); |
4 | | (14) N-methyl-3-piperidyl benzilate; |
5 | | (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
|
6 | | (also known as N-hydroxy-alpha-methyl-
|
7 | | 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA); |
8 | | (15) Parahexyl; some trade or other names:
|
9 | | 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
|
10 | | dibenzo (b,d) pyran; Synhexyl; |
11 | | (16) Psilocybin; |
12 | | (17) Psilocyn; |
13 | | (18) Alpha-methyltryptamine (AMT); |
14 | | (19) 2,5-dimethoxyamphetamine
|
15 | | (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA); |
16 | | (20) 4-bromo-2,5-dimethoxyamphetamine
|
17 | | (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
|
18 | | 4-bromo-2,5-DMA); |
19 | | (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
|
20 | | Some trade or other names: 2-(4-bromo-
|
21 | | 2,5-dimethoxyphenyl)-1-aminoethane;
|
22 | | alpha-desmethyl DOB, 2CB, Nexus; |
23 | | (21) 4-methoxyamphetamine
|
24 | | (4-methoxy-alpha-methylphenethylamine;
|
25 | | paramethoxyamphetamine; PMA); |
26 | | (22) (Blank); |
|
| | 09700HB5233sam002 | - 15 - | LRB097 20167 RPM 68732 a |
|
|
1 | | (23) Ethylamine analog of phencyclidine.
|
2 | | Some trade or other names:
|
3 | | N-ethyl-1-phenylcyclohexylamine,
|
4 | | (1-phenylcyclohexyl) ethylamine,
|
5 | | N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE; |
6 | | (24) Pyrrolidine analog of phencyclidine. Some trade |
7 | | or other names:
1-(1-phenylcyclohexyl) pyrrolidine, PCPy, |
8 | | PHP; |
9 | | (25) 5-methoxy-3,4-methylenedioxy-amphetamine; |
10 | | (26) 2,5-dimethoxy-4-ethylamphetamine
|
11 | | (another name: DOET); |
12 | | (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
|
13 | | (another name: TCPy); |
14 | | (28) (Blank); |
15 | | (29) Thiophene analog of phencyclidine (some trade
|
16 | | or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
|
17 | | 2-thienyl analog of phencyclidine; TPCP; TCP); |
18 | | (30) Bufotenine (some trade or other names:
|
19 | | 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
|
20 | | 3-(2-dimethylaminoethyl)-5-indolol;
|
21 | | 5-hydroxy-N,N-dimethyltryptamine;
|
22 | | N,N-dimethylserotonin; mappine); |
23 | | (31) 1-Pentyl-3-(1-naphthoyl)indole |
24 | | Some trade or other names: JWH-018; |
25 | | (32) 1-Butyl-3-(1-naphthoyl)indole |
26 | | Some trade or other names: JWH-073; |
|
| | 09700HB5233sam002 | - 16 - | LRB097 20167 RPM 68732 a |
|
|
1 | | (33) 1-[(5-fluoropentyl)-1H-indol-3-yl]- |
2 | | (2-iodophenyl)methanone |
3 | | Some trade or other names: AM-694; |
4 | | (34) 2-[ ( 1R,3S)-3-hydroxycyclohexyl]-5- |
5 | | (2-methyloctan-2-yl)phenol |
6 | | Some trade or other names: CP 47,497 47, 497 |
7 | | and its C6, C8 and C9 homologs; |
8 | | (34.5) (33) 2-[(1R,3S)-3-hydroxycyclohexyl]-5- |
9 | | (2-methyloctan-2-yl)phenol), where side chain n=5; |
10 | | and homologues where side chain n=4, 6, or 7; Some |
11 | | trade or other names: CP 47,497; |
12 | | (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3- |
13 | | (2-methyloctan-2-yl)-6a,7, |
14 | | 10,10a-tetrahydrobenzo[c]chromen-1-ol |
15 | | Some trade or other names: HU-210; |
16 | | (35.5) (34) (6aS,10aS)-9-(hydroxymethyl)-6,6- |
17 | | dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- |
18 | | tetrahydrobenzo[c]chromen-1-ol, its isomers, |
19 | | salts, and salts of isomers; Some trade or other |
20 | | names: HU-210, Dexanabinol; |
21 | | (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)- |
22 | | 6,6-dimethyl-3-(2-methyloctan-2-yl)- |
23 | | 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol |
24 | | Some trade or other names: HU-211; |
25 | | (37) (2-methyl-1-propyl-1H-indol- |
26 | | 3-yl)-1-naphthalenyl-methanone |
|
| | 09700HB5233sam002 | - 17 - | LRB097 20167 RPM 68732 a |
|
|
1 | | Some trade or other names: JWH-015; |
2 | | (38) 4-methoxynaphthalen-1-yl- |
3 | | (1-pentylindol-3-yl)methanone |
4 | | Some trade or other names: JWH-081; |
5 | | (39) ( 1-Pentyl-3-(4-methyl-1-naphthoyl)indole |
6 | | Some trade or other names: JWH-122; |
7 | | (40) 2-(2-methylphenyl)-1-(1-pentyl- |
8 | | 1H-indol-3-yl)-ethanone |
9 | | Some trade or other names: JWH-251; |
10 | | (41) 1-(2-cyclohexylethyl)-3- |
11 | | (2-methoxyphenylacetyl)indole |
12 | | Some trade or other names: RCS-8, BTW-8 and SR-18 ; . |
13 | | (42) (33) Any compound structurally derived from |
14 | | 3-(1-naphthoyl)indole or 1H-indol-3-yl- |
15 | | (1-naphthyl)methane by substitution at the |
16 | | nitrogen atom of the indole ring by alkyl, haloalkyl, |
17 | | alkenyl, cycloalkylmethyl, cycloalkylethyl or |
18 | | 2-(4-morpholinyl)ethyl whether or not further |
19 | | substituted in the indole ring to any extent, whether |
20 | | or not substituted in the naphthyl ring to any extent; |
21 | | (43) (34) Any compound structurally derived from |
22 | | 3-(1-naphthoyl)pyrrole by substitution at the nitrogen |
23 | | atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, |
24 | | cycloalkylmethyl, cycloalkylethyl or |
25 | | 2-(4-morpholinyl)ethyl, whether or not further |
26 | | substituted in the pyrrole ring to any extent, whether |
|
| | 09700HB5233sam002 | - 18 - | LRB097 20167 RPM 68732 a |
|
|
1 | | or not substituted in the naphthyl ring to any extent; |
2 | | (44) (35) Any compound structurally derived from |
3 | | 1-(1-naphthylmethyl)indene by substitution |
4 | | at the 3-position of the indene ring by alkyl, haloalkyl, |
5 | | alkenyl, cycloalkylmethyl, cycloalkylethyl or |
6 | | 2-(4-morpholinyl)ethyl whether or not further |
7 | | substituted in the indene ring to any extent, whether |
8 | | or not substituted in the naphthyl ring to any extent; |
9 | | (45) (36) Any compound structurally derived from |
10 | | 3-phenylacetylindole by substitution at the |
11 | | nitrogen atom of the indole ring with alkyl, haloalkyl, |
12 | | alkenyl, cycloalkylmethyl, cycloalkylethyl or |
13 | | 2-(4-morpholinyl)ethyl, whether or not further |
14 | | substituted in the indole ring to any extent, whether |
15 | | or not substituted in the phenyl ring to any extent; |
16 | | (46) (37) Any compound structurally derived from |
17 | | 2-(3-hydroxycyclohexyl)phenol by substitution |
18 | | at the 5-position of the phenolic ring by alkyl, |
19 | | haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl |
20 | | or 2-(4-morpholinyl)ethyl, whether or not substituted |
21 | | in the cyclohexyl ring to any extent ; . |
22 | | (47) (33) 3,4-Methylenedioxymethcathinone |
23 | | Some trade or other names: Methylone; |
24 | | (48) (34) 3,4-Methyenedioxypyrovalerone |
25 | | Some trade or other names: MDPV; |
26 | | (49) (35) 4-Methylmethcathinone |
|
| | 09700HB5233sam002 | - 19 - | LRB097 20167 RPM 68732 a |
|
|
1 | | Some trade or other names: Mephedrone; |
2 | | (50) (36) 4-methoxymethcathinone; |
3 | | (51) (37) 4-Fluoromethcathinone; |
4 | | (52) (38) 3-Fluoromethcathinone ; . |
5 | | (53) (35) 2,5-Dimethoxy-4-(n)-propylthio- |
6 | | phenethylamine; |
7 | | (54) (36) 5-Methoxy-N,N-diisopropyltryptamine ; . |
8 | | (55) Pentedrone. |
9 | | (e) Unless specifically excepted or unless listed in |
10 | | another
schedule, any material, compound, mixture, or |
11 | | preparation which contains
any quantity of the following |
12 | | substances having a depressant effect on
the central nervous |
13 | | system, including its salts, isomers, and salts of
isomers |
14 | | whenever the existence of such salts, isomers, and salts of
|
15 | | isomers is possible within the specific chemical designation: |
16 | | (1) mecloqualone; |
17 | | (2) methaqualone; and |
18 | | (3) gamma hydroxybutyric acid. |
19 | | (f) Unless specifically excepted or unless listed in |
20 | | another schedule,
any material, compound, mixture, or |
21 | | preparation which contains any quantity
of the following |
22 | | substances having a stimulant effect on the central nervous
|
23 | | system, including its salts, isomers, and salts of isomers: |
24 | | (1) Fenethylline; |
25 | | (2) N-ethylamphetamine; |
26 | | (3) Aminorex (some other names:
|
|
| | 09700HB5233sam002 | - 20 - | LRB097 20167 RPM 68732 a |
|
|
1 | | 2-amino-5-phenyl-2-oxazoline; aminoxaphen;
|
2 | | 4-5-dihydro-5-phenyl-2-oxazolamine) and its
|
3 | | salts, optical isomers, and salts of optical isomers; |
4 | | (4) Methcathinone (some other names:
|
5 | | 2-methylamino-1-phenylpropan-1-one;
|
6 | | Ephedrone; 2-(methylamino)-propiophenone;
|
7 | | alpha-(methylamino)propiophenone; N-methylcathinone;
|
8 | | methycathinone; Monomethylpropion; UR 1431) and its
|
9 | | salts, optical isomers, and salts of optical isomers; |
10 | | (5) Cathinone (some trade or other names:
|
11 | | 2-aminopropiophenone; alpha-aminopropiophenone;
|
12 | | 2-amino-1-phenyl-propanone; norephedrone); |
13 | | (6) N,N-dimethylamphetamine (also known as:
|
14 | | N,N-alpha-trimethyl-benzeneethanamine;
|
15 | | N,N-alpha-trimethylphenethylamine); |
16 | | (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
|
17 | | 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine); |
18 | | (8) 3,4-Methylenedioxypyrovalerone (MDPV). |
19 | | (g) Temporary listing of substances subject to emergency |
20 | | scheduling.
Any material, compound, mixture, or preparation |
21 | | that contains any quantity
of the following substances: |
22 | | (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
|
23 | | (benzylfentanyl), its optical isomers, isomers, salts,
|
24 | | and salts of isomers; |
25 | | (2) N-[1(2-thienyl)
|
26 | | methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl),
|
|
| | 09700HB5233sam002 | - 21 - | LRB097 20167 RPM 68732 a |
|
|
1 | | its optical isomers, salts, and salts of isomers. |
2 | | (Source: P.A. 96-347, eff. 1-1-10; 96-1285, eff. 1-1-11; |
3 | | 97-192, eff. 7-22-11; 97-193, eff. 1-1-12; 97-194, eff. |
4 | | 7-22-11; 97-334, eff. 1-1-12; revised 9-14-11.)
|
5 | | Section 15. The Drug Paraphernalia Control Act is amended |
6 | | by changing Section 2 as follows:
|
7 | | (720 ILCS 600/2) (from Ch. 56 1/2, par. 2102)
|
8 | | Sec. 2. As used in this Act, unless the context otherwise |
9 | | requires:
|
10 | | (a) The term "cannabis" shall have the meaning ascribed to |
11 | | it in Section
3 of the Cannabis Control Act, as if that |
12 | | definition were incorporated
herein.
|
13 | | (b) The term "controlled substance" shall have the meaning |
14 | | ascribed to
it in Section 102 of the Illinois Controlled |
15 | | Substances Act, as if that
definition were incorporated herein.
|
16 | | (c) "Deliver" or "delivery" means the actual, constructive |
17 | | or attempted
transfer of possession, with or without |
18 | | consideration, whether or not there
is an agency relationship.
|
19 | | (d) "Drug paraphernalia" means all equipment, products and |
20 | | materials of
any kind, other than methamphetamine |
21 | | manufacturing materials as defined in Section 10 of the |
22 | | Methamphetamine Control and Community Protection Act, which |
23 | | are intended to be used unlawfully in planting, propagating,
|
24 | | cultivating, growing, harvesting, manufacturing, compounding,
|
|
| | 09700HB5233sam002 | - 22 - | LRB097 20167 RPM 68732 a |
|
|
1 | | converting, producing, processing, preparing, testing, |
2 | | analyzing, packaging,
repackaging, storing, containing, |
3 | | concealing, injecting, ingesting, inhaling
or otherwise |
4 | | introducing into the human body cannabis or a controlled |
5 | | substance
in violation of the Cannabis Control Act, the |
6 | | Illinois Controlled
Substances
Act, or the Methamphetamine |
7 | | Control and Community Protection Act or a synthetic drug |
8 | | product or misbranded drug in violation of the Illinois Food, |
9 | | Drug and Cosmetic Act . It
includes, but is not limited to:
|
10 | | (1) kits intended to be used unlawfully in |
11 | | manufacturing, compounding,
converting,
producing, |
12 | | processing or preparing cannabis or a controlled |
13 | | substance;
|
14 | | (2) isomerization devices intended to be used |
15 | | unlawfully in increasing
the potency of any species of |
16 | | plant which is cannabis or a controlled
substance;
|
17 | | (3) testing equipment intended to be used unlawfully in |
18 | | a private home for
identifying
or in analyzing the |
19 | | strength, effectiveness or purity of cannabis or |
20 | | controlled
substances;
|
21 | | (4) diluents and adulterants intended to be used |
22 | | unlawfully for cutting
cannabis
or a controlled substance |
23 | | by private persons;
|
24 | | (5) objects intended to be used unlawfully in |
25 | | ingesting, inhaling,
or otherwise introducing cannabis, |
26 | | cocaine, hashish, or hashish oil , or a synthetic drug |
|
| | 09700HB5233sam002 | - 23 - | LRB097 20167 RPM 68732 a |
|
|
1 | | product or misbranded drug in violation of the Illinois |
2 | | Food, Drug and Cosmetic Act into
the human body including, |
3 | | where applicable, the following items:
|
4 | | (A) water pipes;
|
5 | | (B) carburetion tubes and devices;
|
6 | | (C) smoking and carburetion masks;
|
7 | | (D) miniature cocaine spoons and cocaine vials;
|
8 | | (E) carburetor pipes;
|
9 | | (F) electric pipes;
|
10 | | (G) air-driven pipes;
|
11 | | (H) chillums;
|
12 | | (I) bongs;
|
13 | | (J) ice pipes or chillers;
|
14 | | (6) any item whose purpose, as announced or described |
15 | | by the seller, is
for use in violation of this Act.
|
16 | | (Source: P.A. 93-526, eff. 8-12-03; 94-556, eff. 9-11-05 .)
|
17 | | Section 99. Effective date. This Act takes effect upon |
18 | | becoming law.".
|